CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Metabasis Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Metabasis Therapeutics, Inc.
11119 North Torrey Pines Road
Phone: (858) 587-2770p:858 587-2770 La Jolla, CA  92037  United States Ticker: MBRX MBRX
This company was Merged or Acquired on 1/28/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Metabasis Therapeutics, Inc. (Metabasis) is a biopharmaceutical company focused on the discovery development of drugs. The Company’s product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets. All of its product candidates were developed internally using its HepDirect technology. The Company’s pipeline of clinical-stage product candidates also consists of its core asset, MB07803, a product candidate for the treatment of type 2 diabetes, and its non-core assets, pradefovir and MB07133, developed for the treatment of hepatitis B and primary liver cancer, respectively. In January 2010, Ligand Pharmaceuticals Incorporated completed the acquisition of Metabasis.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200912/31/2008YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Acting Principal Executive Officer David F.Hale 60 10/30/2009 4/1/1997
Chief Financial Officer, VP - Finance, Principal Accounting Officer, Treasurer, Secretary Tran B.Nguyen 35 10/26/2009 3/2/2009
Director Paul K.Laikind 53 12/9/2008 4/1/1997
4 additional Officers and Directors records available in full report.

Business Names
Business Name
MBRX
METABASIS THERAPEUTICS INC

General Information
Number of Employees: 52 (As of 3/30/2009)
Outstanding Shares: 35,157,359 (As of 11/9/2009)
Shareholders: 100
Stock Exchange: NASD
Federal Tax Id: 330753322
Fax Number: (858) 458-3504


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023